NCT06239623View on ClinicalTrials.gov

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

April 2, 2022

Primary Completion Date

September 28, 2024

Study Completion Date

December 30, 2024

Conditions

Solid TumorNSCLCMelanoma

Interventions

DRUG

JSI-1187

Use ERK inhibitor JSI-1187 to treat solid tumor

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

JS InnoPharm, LLC

All Listed Sponsors

lead

JS InnoPharm, LLC

INDUSTRY